Inclusion Criteria:  Patients who are 20 years of age and older, having Covid-19 PCR positivity in the nasopharyngeal swab and showing symptoms of Covid-19 (fever, cough, dyspnea, joint pain, etc.) with or without involvement in lung imaging. Patients may have hypertension disease and type II diabetes mellitus (occurring less than 5 years, diet and/or insulin-regulated). HbA1C levels of all participants (HbA1C < 6.4%) will be studied to confirm if any patient in the study or control groups has unregulated DM or undiagnosed overlooked DM. Diabetic patients with an HbA1C level above 6.4% will be excluded from the study. Enrolled patients have to have a diagnostic chest X-ray and/or HRCT. (Participants will be subjected to radiological classification and scoring according to lung involvement such as ground-glass opacity.)  Exclusion Criteria:  Patients who are considered to have previous vascular endothelial damage due to secondary causes such as history of thrombosis, thrombophlebitis and/or thromboembolism, Presence of active cancer, history of chemotherapy, radiotherapy or bone marrow transplantation, Presence or history of autoimmune, connective tissue diseases, vasculitis (autoimmune thyroiditis, Crohn's, ulcerative colitis, SLE, Sjogren's disease, etc.), Familial inherited hereditary diseases (Hemophilia, Mediterranean anemia, FMF, Thalassemia major etc.) Patients with chronic renal failure and/or requiring dialysis, Presence of acquired/congenital immunodeficiency, Patients who are receiving immunosuppressive or biologic drug therapy, Patients receiving treatment with a diagnosis of bronchial asthma, Type 1 or type 2 diabetes mellitus patients with HbA1C levels > 6.4% Patients with diabetes for more than 5 years or currently taking oral insulin-sensitizing drugs (biguanides; metformin) Patients using antithrombotic (Clopidogrel, low-dose aspirin, etc.) and anticoagulant (LMWH, Warfarin, etc.) agents due to comorbid disease at the time of diagnosis. Patients using ACE inhibitors such as lisinopril as an antihypertensive agent